Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin, Burak; Sendur, Mehmet; Yucel, Sebnem; Celik, Emir; Ozyukseler, Deniz; Ayhan, Murat; BAŞOĞLU TÜYLÜ, TUĞBA; Ilhan, Aysegul; Akdeniz, Nadiye; Gulmez, Ahmet; Dogan, Izzet; AKTAŞ, BURAK; Gurbuz, Mustafa; KOCA, SİNAN; PAYDAŞ, SEMRA; TATLI, ALİ; Cinkir, Havva; Alan, ÖZKAN; Erol, Cihan; Hizal, Mutlu; Kut, Engin; Menevse, Serkan; Sakalar, Teoman; Taskaynatan, Halil; Deniz, Gulhan; Karaagac, Mustafa; Avci, Okan; Sen, Erdem; KARATAŞ, FATİH; Akinci, Muhammed; Dede, Didem; Demir, ATAKAN; DEMİRKAZIK, AHMET; Oksuzoglu, Berna; Kilickap, Sadettin; Yumuk, Fulden; Yalcin, Bulent

doi:10.1007/s00432-020-03501-6

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 147 Sayı: 7
Basım Tarihi: 2021
Doi Numarası: 10.1007/s00432-020-03501-6
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.2145-2152
Anahtar Kelimeler: Afatinib, Erlotinib, Exon 19 del, Gefitinib, NSCLC
İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that investigate the efficacy and safety of the new generation TKIs in real-world patients. Thus, we aimed to compare the efficacy and safety of the afatinib, an irreversible inhibitor of ErbB family receptor, and first-generation TKIs in real-world patients.